September 29, 2020
Fusion Pharmaceuticals Appoints Maria Stahl As Chief Legal Officer
Media
September 28, 2020
GenSight Biologics Announces Publication of Meta-Analysis Confirming that Spontaneous Recovery in LHON is rare in the Journal of Neuro-Ophthalmology
September 25, 2020
Invitation – Orexo Digital Therapeutics business update October 1
September 25, 2020
Robust effects of VP01 in human idiopathic pulmonary fibrosis lung tissue
September 23, 2020
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease
September 23, 2020
Nordic Nanovector ASA – Key information regarding potential repair offering
September 23, 2020
Nordic Nanovector – Private placement successfully completed
September 22, 2020
Digital Therapies Help Frontline Workers Cope
September 21, 2020
Camel-IDS enters next stage with name change to PRECIRIX® and IND approval for CAM-H2 Phase I/II study
September 21, 2020
GenSight Biologics reports new analysis demonstrating statistically significant and clinically meaningful difference between visual outcomes in LUMEVOQ®-treated patients and natural history of Leber Hereditary Optic Neuropathy (LHON)
